Liposomal bupivacaine plus bupivacaine versus ropivacaine for PENG block in hip replacement
Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for PENG Block on Post Operative Pain Management in Patients Undergoing Hip Arthroplasty: a Prospective, Randomized, Single Blind, Active Controlled Study
This trial will test whether adding liposomal bupivacaine to regular bupivacaine for a pericapsular nerve group (PENG) block gives longer and better pain relief than ropivacaine after hip replacement surgery.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06565910 on ClinicalTrials.gov |
What this trial studies
This is a single-center, phase 4 interventional trial enrolling patients undergoing hip arthroplasty for hip fracture who meet ASA I–II and normal coagulation criteria. Participants receive a PENG block and are assigned to receive either liposomal bupivacaine plus standard bupivacaine or ropivacaine. The study compares pain relief duration, overall analgesic efficacy, opioid consumption, patient satisfaction, and records adverse events to assess safety. Outcomes are measured in the immediate postoperative period and during standard postoperative follow-up.
Who should consider this trial
Good fit: Adults having hip arthroplasty for hip fracture who are ASA physical status I–II, have normal coagulation, and have no allergy to amide local anesthetics are the intended participants.
Not a fit: Patients with severe systemic disease (ASA III or higher), abnormal coagulation, or an allergy to amide local anesthetics would not be eligible and are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, this approach could provide longer-lasting pain relief after hip replacement and reduce the need for opioid medications.
How similar studies have performed: Liposomal bupivacaine has produced longer analgesia in some wound infiltration and peripheral block studies, but results are mixed and specific evidence for PENG block remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * American Society of Anesthesiologists(ASA) I\~II * Normal coagulation * Clinical diagnosis of hip fracture Exclusion Criteria: * Presence of severe systemic diseases or ASA grade III or higher * Allergy to amide local anesthetics
Where this trial is running
Wuhan, Hubei
- Department of Anesthesiology, Tongji Hospital, Tongji Medical College, HUST — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Xijian KE, MD
- Email: kexijian@hust.edu.cn
- Phone: 13429826148
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.